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Neuromuscular transmission and its pharmacological blockade 
Part 1: Neuromuscular transmission and general aspects of its blockade
• Leo H. D. J . Boolj
1.1 .Introduction
Muscle relaxation is an important tool in the treat­
ment of patients during anaesthesia for surgical and 
diagnostics procedures, and during treatment in the 
intensive care unit. Such muscle relaxation is obtained 
by pharmacological intervention with neuromuscular 
transmission with either depolarizing or non-depolar- 
izing relaxants. Suxamethonium presently is the only 
depolarizer in clinical use, but has many adverse 
effects. A large number of non-depolarizing relaxants 
has been introduced into clinical practice; however, 
none of them matches perfectly with the 'ideal mus­
cle relaxant7. This demands the development of new 
compounds. Some of the new development in neuro­
muscular transmission and its blockers are discussed.
1.2.Neurom uscular transm ission
For normal muscular functions an impulse must be 
transferred from the nerve terminal to the muscle. 
Such a transfer takes place at the neuromuscular junc­
tion, which consist of the nerve terminal, a 50-100 
nm wide junctional cleft, and the postjunctional mus­
cle membrane [1],
In research on the neuromuscular junction it has 
been proven that the various morphological struc­
tures and their molecular interactions did not change 
significantly during evolution. Therefore, the results 
found in other species, and in different neurotrans­
mitter involved transfer systems, can be extrapolated 
tot the neuromuscular junction in humans.
1.2.1. The junctional cleft
The cleft forms a physical barrier to the continuity of 
the nerve impulse, that only can be bridged by a neu­
rotransmitter, in this case acetylcholine (Fig. 1.1). The 
junctional cleft contains a basement membrane on 
which acetylcholinesterase is located. Acetylcholine­
sterase is produced in the nerve terminal and is 
secreted into the cleft. Its concentration is highly 
depending on nerve activity [2 3]. It is involved in the 
rapid specific hydrolytic breakdown of acetylcholine 
[4-6]. Each molecule of acetylcholinesterase can bind 
six molecules of acetylcholine [7]. Each binding site of 
the enzyme acetylcholinsterase possesses two active 
subsites: the esteratic site, which is involved in the 
hydrolysis of the ester binding, and the anionic site, in 
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Blockade of neuromuscular transmission is an important 
feature during anaesthesia and intensive care treatment of 
patients. The neuromuscular junction exists in a 
prejunctional part where acetylcholine is synthesized, stored 
and released in quanta via a complicated vesicular system. In 
this system a number of proteins is involved. Acetylcholine 
diffuses across the junctional cleft and binds to 
acetylcholinereceptors at the postjunctional part, and is 
thereafter metabolized by acetylcholinesterase in the 
junctional cleft. Binding of acetylcholine to its postjunctional 
receptor evokes muscle contraction. Normally a large margin 
of safety exists in the neuromuscular transmission, in various 
situations, apart from up-and-down regulation of 
acetylcholine receptors, adjustment of acetylcholine release 
can occur.
Pharmacological interference can interrupt the 
neuromuscular transmission and causes muscle relaxation. 
For this reason both depolarizing and non-depolarizing 
muscle relaxants are clinically used. The characteristics of an 
ideal clinical muscle relaxant are defined. In the description 
of the pharmacology of the relaxants the importance of 
pharmacodynamic and pharmacokinetic parameters are 
defined. Stereoisomerism plays a role with the relaxants.
Toxins and venoms also interfere with neuromuscular 
transmission, through both pre-and postjunctional 
mechanisms.
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acetylcholine. The destruction of acetylcholine is very 
fast, most of a quantum being metabolized within 1 
ms. It takes ca. 80-100 ¡as to split one acetylcholine 
molecule. Acetylcholinesterase can be blocked by 
anticholinesterases, which on the one hand can 
reverse a non-depolarizing neuromuscular blockade, 
but on the other hand can induce a desensitization 
block.
In the deft a network of fibers, connecting the 
nerve terminal and the muscle membrane, is also 
present. This network ties the two elements together, 
but also forms a preferential pathway for acetylcho­
line diffusion across the cleft»
1.2.2. The nerve terminal
One of the major functions of the nerve terminal is 
the rapid secretion of acetylcholine in response to 
electrical signals. Acetylcholine is synthesized in the 
neuronal cytoplasm [8]. An acetyl group is transferred 
by choline-acetyltransferase from acetylcoenzyme A 
to a choline molecule. The enzyme is produced in the 
cell body of the neuron and transported down the 
axon. Acetylc-CoA is supplied by intracellular meta­
bolic processes [9]. Choline is supplied by uptake 
from the extracellular fluid [10]. Fifty per cent of the 
choline comes from reuptake after acetylcholine 
hydrolysis [11], The uptake is mediated by a sodium- 
dependent mechanism [12]. Choline transport is the 
rate-limiting step for the synthesis of acetylcholine 
[13]. The majority of acetylcholine is stored in vesicles 
(Fig. 1,2) [14]. The filling of the vesicle is mediated by 
an acetylcholine transporter [15]. A membrane-locat- 
ed ATPase-dependent protonpump first pumps pro­
tons into the vesicle. The protons are then exchanged 
for acetylcholine through the acetylcholine transport­
er [16]. Vesamicol is a potent selective inhibitor of 
acetylcholine uptake into prejunctional vesicles (inhi­
bition of refilling) [17]. Each vesicle contains approxi­
mately 10 000 molecules of acetylcholine, and is the 
basis for the quantal release of acetylcholine.
Vesicles containing acetylcholine that are available 
for immediate release, are located near the active 
zones in the nerve terminal (Fig. 1.2) [18]. Also there 
is a reserve store of vesicles that can be mobilized and 
they are located further away from the membrane 
(Fig. 1.2). The active zones are involved in the exocy- 
tosis of acetylcholine, and are located just opposite 
the openings of the junctional folds in the muscle 
membrane. The acetylcholine diffuses across the junc­
tional cleft toward the acetylcholine receptors located 
on the crests of the muscle membrane with a density 
of 10 000-20 000 molecules/¡am2 [19 20]. Each ace­
tylcholine receptor is firmly anchored in the endplate 
by fine cytoskeleton filaments [21]. Together with 
acetylcholine, a series of cotransmitters is released 
which are involved in the normal function of neuro­
muscular transmission. Most of the cotransmitters are 
peptides.
There is a delay of 0.5-0.6 ms between the arrival 
of the action potential at the nerve terminal and the 
discharge of acetylcholine in the synaptic cleft. This 
reflects the occurring prejunctional events [22]. The 
delay is temperature sensitive, increasing with hypo­
thermia [23].
When an action potential reaches the nerve termi­
nal, a depolarization of the prejunctional membrane 
occurs resulting in the opening of voltage-operated
Figure 1.2
Model of storage, exocytosis and endocytosls of acetyl - 
choline vesicles. (A) acetylcholine outside the vesicle, (B) 
empty vesicle contains protons which are replaced with 
acetylcholine by an active transport system, (C) vesicle 
containing acetylcholine and stored in the cytoplasma 
away from the prejunctional membrane (mobiUsable 
acetylcholine store), (D) releasable store of vesicles near 
the active side at the membrane, (E) docking of the vesi - 
cle at the active side, (F) fusion of the vesicle with the 
membrane, (C) release of acetylcholine in the junctional 
deft (exocytosis), (H) recycling of the vesicle (endocyto - 
sis), (i) empty vesicle is reused first for proton uptake
than for acetylcholine.
calcium channels, and a small influx of calcium into 
the cytoplasma. Only 2% of the calcium channels 
need to be opened to finally cause acetylcholine 
release [24]. The initial calcium influx increases the 
membrane conductivity to Ca2+, The intracellular cal­
cium concentration increases and the transmitter 
release machinery is activated by rendering it more 
sensitive to calcium (calcium voltage theory) [25]. 
Ca2+ activates a protein kinase C. This starts the phos­
phorylation of several proteins located on the cytosol­
ic surface of the vesicle (the so-called v-SNAREs, i.e. 
synaptobrevin) docked near the active zones in the 
nerve terminal, and on the cytosolic site of the plas- 
malemma (the so-called t-SNAREs, i.e. syntaxin, Rab, 
SNAP-25) [26]. The two systems recognize each other 
and than interact after activation by synaptotagmin 
and facilitation by RabGTPases, to form the SNARE- 
complex [27]. it leads first to facilitation of the mobil­
ization of vesicles [28]. Synaptotagmin is activated 
and docks vesicles at the active zones through bind­
ing to syntaxin or SNAP-25. Than a second docking 
system, involving synaptobrevin and syntaxin of 
SNAP, is activated, which also removes synaptotag­
min from its site.
Thereafter a site is occupied by rabphillin, which 
binds to Rap (another protein). This causes double 
docking of the vesicle. Fusion of the double docked 
membrane starts and acetylcholine is released. The 
fused vesicle is rapidly replaced by a vesicle from the 
reserve pool of vesicles.
It must be recognized that many neurotoxins act 
by binding to the SNAREs, and in this way disturb 
transmitter release and neuromuscular transmission.
The active zones are rich in calcium channels, and 
thus is it understandable that the process of docking,
fusion, and release is mainly concentrated at these 
active sites [29 30].
The membrane of the fused vesicle is recycled by 
endocytosis, and subsequently refilled with acetylcho­
line (Fig. 1.2). Endocytosis is also a complex process, 
again involving a series of membrane proteins [31]. 
Clathrin coates the membrane that originally consti­
tuted the vesicle, thereupon it invaginates, closes and 
separates from the plasmalemma. The clathrin coat is 
then removed [32]. The whole cycle takes less than a 
minute. Part of vesicle recyling is through immediate 
closure of the vesicle upon release of acetylcholine 
('kiss-and-run') [33]. An important protein in endocy­
tosis is the GTPase dynamin, which is involved in fis­
sion of the clathrin-coated vesicles [34]. Dynamin 
forms a ring around the stalk of the vesicle [35]. 
Vesicles are also produced by budding off from endo- 
somes, after coating with clathrin [36]. Fission is 
obtained with dynamin. The recycled vesicles cluster. 
In this process synapsin, a protein bound on the cyto­
solic vesicle surface, is involved [37]. Synapsin also 
binds the vesicles to the cytoskeleton (vesicle cluster­
ing). Endocytosis is triggered by intracellular calcium.
One quantum of acetylcholine is released upon 
fusion of one single vesicle with the prejunctional 
membrane [38]. Upon a depolarizing nerve impulse, 
400-500 quanta of acetylcholine (each 2000-10 000 
molecules) are released. The discharge of acetylcho­
line molecules in the cleft must be fast in order to 
reach the necessary high concentration in the recep­
tor area, and thus cannot depend on diffusion [39].
Apart from quanta! release, non-quantal release of 
acetylcholine also occurs. Cytoplasmic acetylcholine 
leaks continuously into the junctional cleft. With 
nerve stimulation there is some increase in the release 
of cytoplasmatic acetlylcholine [40]. Vesicles can also 
release acetylcholine spontaneously. The spontaneous 
release of acetylcholine causes miniature endplate 
potentials that are not able to depolarize the muscle 
cell membrane, but seems to play a tonic and trophic 
role for the muscle. Upon nerve stimulation acetyl­
choline is released in quanta by exocytosis of the vesi­
cle. Sufficient miniature endplate potentials are then 
present, which summate and cause an endplate 
potential [41]. The number of acetylcholine quanta 
released is in excess of the amount required to evoke 
the actual degree of endplate depolarization for mus­
cle contraction.
Only a limited amount of acetylcholine is available 
for immediate release, the remainder is stored in a 
depot or back-up store [42 43]. Apparently the nor­
mal level of transmitter mobilization is unable to sup­
ply sufficient acetylcholine for high frequency release. 
At high stimulation rates more acetylcholine must be 
mobilized. Mobilization is the process by which the 
nerve supply of acetylcholine is moved into the 
immediately available compartment as it is depleted 
by the process of vesicular exocytosis. The mobiliza­
tion and release of acetylcholine is modulated by pre­
junctional acetylcholine autoreceptors. In this process 
both nicotinic and muscarinic autoreceptors are 
involved. The nicotinic prejunctional receptors serve a 
positive feedback mechanism: they enhance mobil­
ization of acetylcholine [44], Muscarinic autorecep­
tors serve as a negative feed-back mechanism: they 
stop aecetylcholine release when enough transmitter 
is present [45]. Similar effects have been found for the
cholinergic transmission in brain and bronchial 
smooth muscles [46 47]. The prejunctional acetylcho­
line receptors contain only a  and [3 subunits (see 
later) [48]. They, however, consist of several subtypes 
of a and p strains. Acetylcholine receptor antagonists 
(non-depolarizing muscle relaxants) decrease the ace­
tylcholine mobilization and release by occupation of 
presynaptic receptors [49]. Tetanic and train-of-four 
fade (see Part 3) are generally ascribed to a prejunc­
tional action of the relaxants [50],
1.2*3, The postjunctional membrane
Acetylcholine diffuses across the junctional cleft and 
binds to nicotinic acetylcholine receptors (Fig. 1.3). 
The nicotinic acetylcholine receptor is a transmem­
brane protein, forming a ligand-gated ion channel. 
Each motor endplate contains ca. 10 million acetyl­
choline receptors. The acetylcholine receptor is con­
stituted of 5 homologous subunits (Fig. 1.3), a 2 |3 e ô 
in mature receptors and a 2 P y ô in immature recep­
tors [51 52]. During maturation of the neuromuscular 
junction the y-subunits are thus replaced by e-sub­
units [53]. ARIA (acetylcholine receptor inducing 
activity), produced in the nerve terminal and secreted 
into the cleft, is involved in this replacement, and 
stimulates the production of acetylcholine receptors 
[54 55].
Figure 1.3
The 5 subunits of the acetyfchoiine receptor from an ion
channel embedded in the membrane lipid layer.
However, ARIA has no effect on receptor accumula­
tion. The maturation of the receptor results in acceler­
ation of channel conductance, which is mediated by 
one single amino acid [56], It was recently demon­
strated that during development of muscles, most 
ARIA is produced by the muscles [57]. With nicotinic 
receptors some subtypes do exist, depending on the 
structure of the a-subunit [58].
Each subunit contains ca. 2330 amino acids. The 
order of the subunits is clockwise, a|3 a y  6 (imma­
ture) and a(3 as 6 (mature). The molecular weight of 
the a-subunit is 35 000 Dalton, of the p-subunit 
37 000 Dalton, of the y-subunit45 000 Dalton, and 
the 6-subunit 44 000 Dalton [59]. Two receptors are 
always tied together with a disulfide bridge between 
their 5-subunits. When the bridges are disturbed, the 
functioning of the receptor is not interrupted.
immature receptors are present in neonates and 
outsite the neuromuscular junction (after denervation 
and other disease states) [61]. Neuropeptides (sciatin,
calcitonine gene-related peptide, agrin, aria) released 
from the nerve are believed to keep the acetylcholine 
receptors in the endplate region [62 63], An essential 
one in this regard is Agrin, a nerve-derived extracellu­
lar matrix protein that provides the signal for induc­
tion of acetylcholine clustering [64]. The neuronal 
nicotinic acetylcholine receptor is also a pentamer, 
but consists only in 1 or 2 different subunits [65]. 
Acetylcholine receptors are also fixed in the mem­
brane with a number of proteins (laminin, rapsyn, 
utrophin, syntrophin, dystroglycan), some of which 
are extracellular, some intramembranous, and others 
intracellular [66].
The subunits form a large, relatively non-selective 
pore that allows passage of almost all cations with 
diameters of less than 6-7A [67]. At its entrace the 
width is ca. 40 A, and it narrows to ca. 7 A in diameter 
at the level of the membrane surface [68]. Thereafter 
the diameter remains the same. At the extracellular 
side the receptor sticks ca. 60 A into the cleft, the 
intramembranous part is ca. 40 A long and the intra­
cellular part ca. 20 A. The open channel has an exter­
nal width of 80 A and a smallest width (in the mem­
brane) of 6.5 A [69], The ion-channel opens upon 
binding of acetylcholine to both its a-subunits [70]. 
Apart from the high-affinity binding sites there are 
some low-affinity sites, which are involved in activa­
tion and desensitization of the receptor [71]. Other 
compounds than acetylcholine can also bind to such 
places, and thus interfere with the functioning of the 
ion channel.
The ion flux after ion channel opening results in a 
fall in muscle membrane potential, i.e. an endplate 
potential occurs. If sufficient quanta of acetylcholine 
are released the endplate potential will reach a 
threshold to activate voltage-dependent sodium ion- 
channels of the adjacent muscle membrane, thereby 
initiating an action potential and depolarization of the 
muscle membrane. This occurs when at least 5-20% 
of the ion-channels are opened. One quantum of ace­
tylcholine is able to open ca. 1500 channels, causing 
an endplate potential of about 4mA. At the peak of an 
endplate potential ca. 340 000 channels are open, 
through each of which approximately 10 000 cations 
traverse during a mean channels open time. As a 
result the Donan equilibrium over the membrane is 
disturbed with a reduction in membrane potential. 
The residence time of each acetylcholine molecule on 
the receptor is only sufficient to activate one receptor 
molecule. Before it can affect another receptor, ace­
tylcholine is hydrolyzed by acetylcholinesterase, or is 
diffused away.
The various acetylcholine receptor subunits are 
encoded in genes. The genetic information is tran­
scribed into mRNA; they then direct the synthesis of 
subunits by ribosomes in the endoplasmic reticulum. 
The a-subunit can bind agonists already in the ribo­
somes, the subunits thus have undergone so-called 
conformational maturation. Partial assembly of sub- 
units occurs in the endoplasmic reticulum, and so 
does the critical addition of carbohydrates [72], 
Membrane lipoprotein is added, and the final product 
assembled into a vesicle, which is transported to the 
cell surface. Here the vesicle fuses with the mem­
brane, incorporating the receptor in it.
Incorporation of the receptor in the membrane 
takes ca. 3 h [73]. With denervation the synthesis of
acetylcholine receptors is enormously increased [74]. 
Also the encoding of the a-subunit is increased after 
denervation [75],
Acetylcholine receptors are broken down. This 
involves an ATP-dependent internalization of the 
receptors and proteolysis in the lysosomes. The turn­
over time of acetylcholine receptors is usually 2 weeks 
for junctional receptors, and less than 1 day for extra- 
junctional receptors.
The metabolic stability of the receptors is con­
trolled exclusively by evoked muscle activity.
1.2.4. The muscle
Muscle fibres are divided in fast and slow contracting 
fibres. Each muscle fibre contains myofibrils constitut­
ed of filaments of interdigitating actin and myosin, 
mitochondria, and the sarcoplasmic reticulum. The 
reticulum has a function in storing the calcium ions 
necessary for contraction. At rest these proteins are 
inhibited by troponin and tropomyosin. When a high 
calcium concentration is present after depolarization 
of the membrane, an interaction between actin and 
myosin occurs and bridges are formed, The filaments 
then slide along each other and muscle contraction is 
seen. When formation of calcium bridges ceases, the 
muscle relaxes.
The capacity to contract and develop tension is 
modulated by the recruitment of more or less motor 
units. Relaxation of the muscle requires the distrac­
tion of calcium from the sarcoplasm [76 77], It is 
taken up in the sarcoplasmic reticulum and bound to 
the protein calsequestrin (43 molecules of calcium 
per molecule calsequestrin).
1.3,The m argin of safety of neurom uscular 
transm ission
Under normal conditions the amount of acetylcholine 
released is abundant, and the number of acetylcholine- 
receptors activated is much larger than the number 
needed to initiate a muscle action potential [78]. 
There is thus a large margin of safety both in the pre­
junctional (acetylcholine release) and postjunctional 
(acetylcholine receptor activation) components of 
neuromuscular transmission [79]. This is reflected in 
the effect of neuromuscular blocking agents. 
Approximately 75% of the acetylcholine receptors 
must be blocked by antagonists before a reduction in 
contraction force can be observed, while at least 95% 
must be blocked before complete absence of contrac­
tion occurs.
1.4.Up- and down-regulation of the acetyl­
choline receptor
In general chronic exposure to agonist does result in a 
down-regulation (decrease in number of receptors) of 
the receptor. Chronic exposure to an antagonists 
leads to up-regulation (increase in number of recep­
tors). This self-regulation constitutes a homeostatic 
regulatory mechanism of membrane receptors. In 
muscle, sympathetic neurons, and in autonomic gan­
glion nicotinic receptors, chronic nicotine exposure 
causes down-regulation [80 81]. However, in brain 
nicotinic acetylcholine receptors it has been demon­
strated that chronic exposure to nicotine (the ago­
nist) results in up-regulation [82 83]. It is caused by
an increase in receptor density, without a change in 
receptor affinity. The muscarinic brain receptors are 
not affected by nicotine [84]. Acetylcholine itself 
causes down-regulation both in muscarinic and nico­
tinic brain receptors [85], Down-regulation is the 
result of internalization of acetylcholine receptors.
Receptor up-regulation is typically associated with 
increased sensitivity for agonists and resistence to 
competitive antagonists, down-regulations is asso­
ciated with hyposensitivity for agonists and extreme 
sensitivity to antagonists. Up-regulation is seen in 
denervation, disuse atrophy, thermal muscle trauma, 
infection, and chronic non-depolarizing relaxant or 
anti-epileptic drug administration [86]. In up-regula- 
tion the e-subunit is replaced by a y-subunit. 
Increased sensitivity to agonist leads to lethal potas­
sium release after suxamethonium administration.
Chronic neuromuscular blockade by competitive 
antagonists leads, even in subparalytic dosages, to 
proliferation of acetylcholine receptors [87]. A cas­
cade of reactions involving multiple proteins occurs in 
docking and fusion of prejunctional vesicles. This 
effect is independent from the up-regulation seen 
from immobilization. Furthermore, in the same study 
it was demonstrated that chronic exposure to an 
antagonist leads to tolerance. It is not certain whether 
the up-regulation is the result of a prejunctional effect 
(decrease in acetylcholine release), or of a postjunc­
tional effect (receptor occupation). The up-regulation 
is accompanied by an increase in extrajunctional ace­
tylcholine receptors. These are responsible for the 
increased sensitivity and potassium release seen with 
suxamethonium administration. Such potassium 
release may cause death [88 89].
Down-regulation of muscle acetylcholine receptors 
has been demonstrated in situations where increased 
acetylcholine concentrations were present [90], It is 
also seen in myasthenia gravis.
1.5.Blockade of prejunctional acetylcho­
line receptors
Prejunctional acetylcholine receptors are, as described 
above, involved in the regulation of acetylcholine 
release. Acetylcholine mobilization and release is aug­
mented in conditions where under normal levels of 
release insufficient acetylcholine is supplied for release 
during high frequency nerve depolarization. 
Pharmacological interference with the presynaptic 
receptors thus has an effect on neuromuscular trans­
mission [91].
Suxamethonium has an agonistic effect on -the 
receptor, and thus stimulates the presynaptic recep­
tor, leading to increased acetylcholine release and 
initial overshoot in response to peripheral nerve stim­
ulation (until paralysis occurs). Clinically used non­
depolarizing muscle relaxants block prejunctional 
acetylcholine receptors [92]. This decreases prejunc­
tional acetylcholine release via a feedback mecha­
nism, and may contribute to muscle relaxation [93- 
95], Decrease in prejunctional acetylcholine release 
results in fade in the responses to tetanic or train-of- 
four stimulation. The amount of fade produced by 
different non-depolarizing drugs varies, and so, pre­
sumably, does the effect on the nerve terminal [96]. 
With tubocurarine it was demonstrated that at low 
frequency stimulation an increase in acetylcholine
occurs, and at high frequency stimulation a decrease. 
With vecuronium only an increase was seen [97]. 
Hexamethonium has the same results as tubocurarine 
[98]. It is suggested that the increase is mediated 
through neuronal-type nicotinic receptors, normally 
reacting in negative feedback on spontaneous acetyl­
choline release, and the decrease by a muscular-type 
receptor, normally reacting in positive feedback on 
evoked release.
Magnesium is an antagonist of the action of cal­
cium in the nerve terminal, and thus will decrease 
acetylcholine release. Some other metals have the 
same effect [99]. The black spider venom, a-latrotox- 
in, increases prejunctional vesicle fusion and inhibits 
vesicle recycling. This depletes the nerve terminal 
from releasable acetylcholine [100].
1.6.B lockade o f postjunctional acety lch o­
line receptors
Occupation of acetylcholine receptors with substanc­
es other than acetylcholine prevents the binding of 
the neurotransmitter with its receptor, and thus may 
lead to inactivation of neuromuscular transmission. 
When an agonist is administered, approximately 25% 
of the receptors need to be occupied (as with acetyl­
choline) to see an effect. With administration of an 
antagonist it must be prevented that 25% of the 
receptors can be occupied by acetylcholine, and thus 
the antagonist must occupy 75% or more of the 
receptors to exert effect [101]. The receptor binding 
is characterized by a constant association and dissoci­
ation of the relaxant or acetylcholine [102]. The rate 
of receptor association (association constant) and dis­
sociation (dissociation constant) determine receptor 
affinity, and thus they are important factors in the 
'onset' and 'offset' of the neuromuscular blockade. As 
long as there is relaxant in the vicinity of the receptor, 
it can be occupied again, and thus neuromuscular 
blockade will be maintained.
The duration of neuromuscular blockade thus 
depends on the concentration of receptor in the 
receptor compartment (biophase). The concentration 
in the biophase is determined by the plasma concen­
tration and the physico-chemical characteristics of the 
relaxant. There is, therefore, a relationship between 
the plasma concentration of the relaxant and recep­
tor occupation [103-106].
When receptors are in the open state, particular 
molecules may enter the channel. Because the chan­
nel does not have the same width along its whole 
length, the molecule will plug the channel. None of 
the channel blocking compounds is clinically used to 
induce neuromuscular relaxation; however, many 
drugs co-administered perioperatively do have this 
effect (for example, antibiotics, steroids, some muscle 
relaxants, anticholinesterases, local anaesthetics, 
inhalational and intravenous anaesthetics), and thus 
they may interfere with neuromuscular transmission 
[107]. Such a channel block is non-stereospecific, 
whereas receptor block is stereospecific.
1.6.1. Depolarizing neuromuscular blockade
Muscle relaxants with a depolarizing mechanism of 
action have an intrinsic effect on the acetylcholine 
receptor. They thus stimulate the opening of the ion- 
channel, resulting in depolarization of the muscle
membrane, causing muscle fasciculations. Since the 
compounds are not metabolized by acetylcholineste­
rase in the synaptic cleft, the receptor remains occu­
pied, and repolarization is impossible, thus leading to 
muscle relaxation. A depolarizing block is character­
ized by decreased contraction force in the response to 
single twitch stimulation (T1). There is no fade in the 
response to tetanic (Tet) or train-of-four (TOF) stimu­
lation. The only clinically used depolarizing muscle 
relaxants is suxamethonium.
1.6.2* Anticholinesterase-induced neuromuscular 
blockade
With sustained presence of acetylcholine at the recep­
tor, receptor desensitization occurs [108]. In the situa­
tion one of the subunits bends and distorts the recep­
tor, so that it no longer responds to an agonist by 
opening the channel [109]. Such a situation can 
occur if acetylcholine is not metabolized due to ace- 
tylcholinesterase inhibition. Overdose of anticholines­
terases have been shown to cause such problems 
[110 111].
1.6.3. Non-depolarizing neuromuscular blockade
The non-depolarizing relaxants bind to the acetylcho­
line receptor, but have no intrinsic effect Therefore 
the ion-channel remains closed, and flaccid paralysis 
is seen. A non-depolarizing block is characterized by 
decreased contraction force on single twitch stimula­
tion (T1), fade in the response to tetanic (TET) and 
train-of-four (TOF) stimulation, and in post-tetanic 
facilitation. Non-depolarizing muscle relaxants are 
charged quarternary nitrogen compounds with a 
fixed interonium distance. They compete with acetyl­
choline for the acetylcholine binding places at the 
two a-subunits of the receptor. More than 75%  of the 
postjunctional receptors must be occupied before an 
effect can be seen [112]. The non-depolarizers jump 
on and off the receptor, exerting effects within ms of 
binding. These compounds also occupy presynaptic 
receptors (results in fading) and ion channels. 
Non-depolarizing muscle relaxants are now used rou­
tinely in clinical anaesthesia and in intensive care, A
Table 1 -1 Requirements for the ideal muscle
relaxant





6. No serious cardiovascular side-effects
7. No histamine release
8. Reversible effect
9. Lack of drug interaction
10. Pharmacological inactive metabolites
11. Independent from organ excretion (liver, kid­
ney)
12. Absence of nervous systems effects (ICU use)
13. Absence of muscular effects (ICU use)
14. Stable in solution/ready for use formulation
wide variety of such compounds have been intro­
duced, e.g. tubocurarine (1942), gallamine (1947 
[113]), alcuronium (1961 [114]), pancuronium (1967
[115]), metocurine (1948 and reintroduced in 1972
[116]), dioxonium (1972 [117]), fazadinium (1974 
[118]), vecuronium (1980 [119 120]), pipecuronium 
(1980 [121]), atracurium (1981 [122 123]), doxacuri- 
um (1988 [124]), mivacurium (1988 [125]), and roc- 
uronium (1991 [126]), Although the newer relaxants 
are nearer to the 'ideal' requirements (see Table 1.1.) 
of a neuromuscular blocker, and provide more flex­
ibility than the older ones, is there still no single com­
pound that can be used in all circumstances.
A large number of experimental relaxants have 
been studied in animals and in a small number of 
patients, but have not come into routine clinical use. 
Examples are tropanyl esters [127], bulky esters (diox- 
onium, diadonium, anatruxonium, cyclobutonium, 
and truxilonium [128], steroidal relaxants (chando- 
nium [129], Org 6368 [130], Org 7617 [131 132], 
Org 8764 [133], Org 9991 [134], and Org 9616 [32], 
and benzylisoquinolines (BW 252C64 [135] and BW 
403C65).
1.6.4. Drugs with a mixed depolarizing and non­
depolarizing mechanism of action
Coryneine, a compound with a quarternary ammo­
nium derivative of dopamine structure, and derived 
from the aconite root, has a relaxant effect which is 
mixed competitive and non-competitive [136], 
Dioxonium is a relaxant with mixed effect, having an 
initial depolarizing mechanism, but with higher dos­
ages converts into a non-depolarizing mechanism 
[137 138]. When the non-depolarizing stage is 
reached, the blockade is reversible by anticholineste­
rases. In studies, cardiovascular or other adverse 
effects were not observed. A disadvantage is that 
these seems to be tachyphylaxis for dioxonium upon 
repeated administration. The clinical value is thus not 
well established.
1.7.The ideal m uscle relaxant
Based on clinical experience with the existing muscle 
relaxants, the requirements for the ideal muscle relax­
ant can be defined (see Table 1.1). Some additional 
'desires' can be defined as well. It would be ideal if 
blockade of particular muscles could be selectively 
obtained. Then, for example, selective blockade of 
the hypopharyngeal and laryngeal muscles would 
make intubation in spontaneously breathing patients 
possible. Selective paralysis of abdominal muscles 
would allow intra-abdominal surgery in spontaneous­
ly breathing patients under general anaesthesia. 
Another desirable point is a smaller variability in 
effect. If it were possible, a gaseous relaxant which 
would depend on ventilation for its elimination, and 
thus being independent from hepatic or renal func­
tion, would seem to be ideal. Organ independency 
could also be reached if metabolism was through 
hydrolysis in plasma, but independent from plasma 
cholinesterase activity. This might be possible if spe­
cific esterases (i.e. carboxylesterase) are involved in 
the metabolism.
1.8.Pharm acodynam ics of m uscle relax­
ants
1,8.1. Potency, latency time, and onset
With non-depolarizing neuromuscular blockers, a cor­
relation between potency and rate of onset appears 
to exists; the less potent the compound, the faster the 
onset [139 140]. With low potency non-depolarizing 
muscle relaxants, recovery is fast, whereas, with high 
potency drugs, it is slow [141]. This may be related to 
a high receptor association rate, making dissociation 
from the receptor more 'difficult' (low dissociation 
constant). This effect may, however, be masked if the 
relaxant remains in the vicinity of the receptor, i.e. if 
the plasma concentration is not decreasing rapidly 
[142]. For short duration of action, low affinity of the 
molecules to the receptor is necessary. This automati­
cally implies low potency. This has recently been con­
firmed to be applicable for the offset of effect of all 
non-depolarizing relaxants, giving in humans the 
sequence of gallamine < rocuronium < tubocurarine < 
atracurium < pancuronium < vecuronium < doxacuri- 
um [143]. Some studies have suggested that the rate 
of diffusion from the plasma to the receptor was more 
important than the rate and affinity of drug-receptor 
association [144]. This agrees with clinical data 
obtained for fazadinium, pancuronium, tubocurarine 
and suxamethonium [145].
Theoretical considerations indicate that onset time 
must have a limit, because it cannot be shorter than 
the circulation time. The circulation time is the short­
est latency time possible. The latency time is further­
more determined by the receptor association rate and 
the amount of relaxant present in the biophase. 
Because ca. 90% of receptors must be blocked for full 
relaxation, and thus an equal number of relaxant 
molecules must be administered, this means that 
potency also is limited. The likely non-depolarizing 
equivalent to suxamethonium would thus have, com­
pared to other compounds in the same chemical 
group of substances, low potency.
A variety of methods to decrease the onset of relax­
ants, and thus to decrease the delay between admin­
istration of the relaxant and endotracheal intubation, 
have been used with the relaxants presently available. 
The onset time of an individual compound decreases 
with an increase in the dose, as has been demonstrat­
ed for atracurium [146] and vecuronium [147]. In a 
clinical study, the administration of respectively 100, 
200, 300, and 400 ng/kg vecuronium in 10 patients 
each demonstrated a decrease in onset time with an 
increase in duration and recovery rate. Side effects, 
however, were not seen [148]. These results were 
confirmed in another study in which the onset time of 
vecuronium halved when 0.3 mg/kg was adminis­
tered instead of 0.1 mg/kg [149]. The duration of 
action, however, was increased markedly with the 
higher doses. This has also been seen with other 
relaxants, but it leads to a marked increase in duration 
of action and side-effects. With the longer acting 
relaxants, the duration of action can become 
extremely long and unpredictable. When larger dos­
ages of relaxants are administered, there is a frequent 
need to antogonize the block produced. With benzyl- 
isoquinolines the increase in dose may lead to hista­
mine release.
With the 'priming principle' technique, one third of
the calculated dose of relaxant is administered 3-5 
min before induction of anaesthesia, the remainder is 
then administered immediately after induction. 
Although it has been demonstrated that the 'priming 
principle' decreases the onset time, there are a num­
ber of unwanted side-effects. In one study, the onset 
times after priming with vecuronium, atracurium and 
pancuronium were compared with that after suxame­
thonium. They approached each other. The optimal 
dose for priming with vecuronium was 0.012 mg/kg, 
pancuronium 0.015 mg/kg, and atracurium 0.09 
mg/kg. The optima! time interval between the doses 
of relaxant was 3-5 min [150], However, with all these 
relaxants, double vision, difficulty with breathing and 
swallowing occurred frequently. This has been con­
firmed in other studies [151 152]. The side-effects of 
priming vary with the interindividual variability in sen­
sitivity for relaxants.
The administration of combinations of particular 
relaxants, e.g. pancuronium and metocurine, galla­
mine and metocurine, and tubocurarine and pancu­
ronium, can lead to a faster onset of action, but it can 
also lead to a potentation or prolongation of effect 
[153]. This can be difficult to predict because of the 
large interindividual variability in response to relax­
ants. The interaction is probably due to the differen­
ces in the mechanism of action of the various relax­
ants. Because some relaxants have a more pro­
nounced presynaptic effect than others, and because 
some cause more ion-channel plugging than others, 
and also because some depend more on redistribu­
tion and others more on metabolism to terminate 
their effects (different pharmacokinetic behaviour), 
marked interactions between relaxants are possible. 
Although the technique of administration of relaxant 
combinations has been advocated in the past, further 
studies are necessary before it can be considered safe 
for routine use. In one study, it was demonstrated 
that rocuronium and mivacurium potentiate each 
other. Not only was the duration of the combination 
longer, but also the onset was shorter Interestingly, a 
combination of 150 ng/kg rocuronium + 37.5 |.ig/kg 
mivacurium produced a blockade with a rapid onset 
(114 s) and short duration (14.7 min); a combination 
of 300 ¡ag/kg rocuronium + 75 t^g/kg mivacurium 
produced a shorter onset (69 s) and a longer duration 
(34 min); a combination of 600 ¿.ig/kg rocuronium + 
150 |.ig/kg mivacurium did not produce a faster 
onset, but did lead to a significantly prolonged dura­
tion (55.2 min) [154]. An explanation for this was not 
given, but may lie in the breakdown of mivacurium 
by plasma cholinesterase. This esterase is usually 
inhibited by aminosteroidal relaxants.
The onset time is not necessarily the same as the 
intubation time. With most relaxants, it is possible to 
intubate the trachea under excellent conditions when 
the neuromuscular blockade, measured at the adduc­
tor pollicis muscle is 70-80%. This is due to the fact 
that the pharmacodynamic profile of the relaxants 
varies with the different muscles. Intubation with roc­
uronium, for example, is possible with excellent con­
ditions, comparable to those after suxamethonium, 
within 60-90 s after administration of twice the ED95 
dose.
1.8.2. Duration of action and recovery rate
The duration of action of a relaxant depends on its
dissociation rate from the receptor and on the 
amount of relaxant in the vicinity of the receptor. This 
amount depends on the dose administered, the rate 
of metabolism, and the rate of (re)distribution and 
elimination. Most relaxants depend on redistribution 
for termination of their effect. Some are rapidly inacti­
vated in the biophase, or have a built-in self-antago­
nistic action, while others are metabolized in the plas­
ma or by enzymatic processes in the liver, or they are 
excreted unchanged via the kidneys. The recovery 
rate also depends on the speed with which the acetyl­
choline receptors are freed from the relaxant. If there 
is a high receptor affinity (i.e. high potency), then the 
relaxant binds again to the receptor. With a lower 
affinity, it may diffuse away, or it may be metabolized. 
The recovery rate is, however, independent from the 
degree of neuromuscular blockade. Depending on 
the pharmacokinetic characteristics of each relaxant, 
organ failure can lead to a change in the pharmacoki­
netic behaviour of the relaxant. This can alter the 
pharmacodynamic profile of the relaxant.
1.9. Pharm acokinetics o f m uscle  relaxants
The pharmacokinetics of the currently used relaxants 
can be described in a two- or three- compartment 
model, with a rapid distribution phase (distributional 
clearance) in which they are transferred from the cen- 
tral compartment (VDC) into one or two peripheral 
compartments (Fig. 1,4). This is followed by one or 
two slower elimination phases, consisting of biotrans­
formation and excretion (metabolic clearance). For 
most relaxants, a two-compartment model is suitable 
and thus two h a if-1 if e times be determined: the half- 
life of distribution (t1/>0[) and the half-life of elimination
Due to the high water solubility the volume of dis­
tribution of relaxants is small. After intravenous 
administration, the initial volume of distribution can 
vary from 80 tot 150 ml/kg, and the subsequent vol­
ume of distribution (central plus peripheral compart­
ment, VDarea or VDSS) from 200 to 450 ml/kg. This is 
somewhere between the volume of the extracellular
water compartment and the total body water in 
humans. VDC governs the peak plasma concentration 
after a rapid bolus injection, and VDSS the tissue pene­
tration of the compound. These distribution volumes 
and the clearances of relaxants can be markedly 
affected by disease states such as hepatic and renal 
failure and cardiovascular disturbances. In hepatic 
and renal diseases, but also in other diseases, the 
metabolism and excretion of drugs may be affected 
leading to changes in plasma clearance (Clp) and t^ . 
They can also change the volumes of distribution. 
Disease states are thus frequently connected with 
changes in the pharmacokinetic behaviour and the 
pharmacodynamic profile of relaxants. Because drug 
distribution in the tissues depends on tissue perfu­
sion, the cardiac output is an important factor in the 
pharmacokinetics of relaxants. Reduction in cardiac 
output usually leads to a redistribution with lengthen­
ing of the tf/a, a slower onset of action, and to a 
greater effect. With increased cardiac output, tissue 
perfusion is elevated. This means more rapid and 
widespread distribution. A higher dose is, therefore, 
needed for the same effect. In hypovolaemic shock, 
the VDC is smaller, and thus a higher peak concentra­
tion occurs. This leads to a greater than normal clini­
cal effect.
Protein binding of muscle relaxants varies between 
30 and 85%, and is another important factor in their 
pharmacokinetic behaviour [155]. Both changes in 
the protein concentration in disease status and bind­
ing of concurrently administered drugs to proteins 
influence the protein binding of relaxants. This bind­
ing can alter the volume of distribution, metabolism, 
and the excretion of the relaxants. Protein binding 
also plays an important role in maternal-foetal drug 
equilibration during pregnancy
1 -10.The effect of animal toxins on neuro­
m uscular transm ission
Many animal toxins have a neuromuscular blocking 
effect, the study of which may be helpful in the future 
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blocking agents. In an excellent review the effect of a 
variety of venoms has been described [156], Some of 
them block neuronal sodium channels (tetrodotoxin, 
saxoitoxin, batrachotoxin, dquatoxin, [i-conotoxin, 
a- and p-scorpiotoxins, sea anemone toxins), potas­
sium channels (dendrotoxin, scorpio toxins, apamin, 
p-bungarotoxin), or nerve terminal calcium channels 
(co-conotoxin, agatoxins, rattelsnake venoms, funnel- 
web toxin). Others inhibit prejunctional acetylcholine 
release (p-bungarotoxin, notexin, crotoxin, taipoxin, 
latrotoxin), block postjunctional acetylcholine recep­
tors (cx-bungarotoxin, cobratoxin, sea snake venom, 
a-conotoxin). The ones inhibiting prejunctional ace­
tylcholine release frequently interfere with the 
SNAREs involved in vesicle docking and fusion [157], 
Yet other toxins interfere with muscle contractility 
(viper venom, honey bee, notexin, scorpio toxin). 
Many of the toxins were used to study the develop­
ment, maturation, and functioning of the neuromus­
cular junction, and to elucidate the effect of chemical 
compounds on neuromuscular transmission, a-latro- 
toxin, the active part of the black widow spider 
venom, causes a reduction in quantal acetylcholine 
release by blockade of exocytosis [158]. A number of 
toxins do irreversibly inhibit acetylcholine receptors. 
Lophotoxins are very specific selective irreversible 
inhibitors of nicotinic acetylcholine receptors [159].
1.11. Stereoisom erism
Many drugs, including some relaxants, are available 
as a racemic mixture of enantiomers. Each enantiom- 
er can have different physicochemical properties, and 
hence can have a different pharmacological profile. 
Some isomers are each other's mirror, but cannot be 
superimposed upon each other. Geometric-isomers 
show cis-trans isomerism. Examples of muscle relax­
ants with isomers are atracurium, containing 10 ster- 
eo-isomers, and mivacurium, containing 3 stereoi­
somers. The 1R-c/s-1 R'-c/s isomer of atracurium (cisat- 
racurium, 51W89) is currently under development as 
a non-depolarizing relaxant.
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